Robert T.S.Latta (Rob)

Partner

San Diego + 1.858.314.1140

Connect:

Share

Rob Latta is an intellectual property transactions lawyer focusing on life sciences and environmental sustainability. He advises clients on a range of life science, agrifood, and technology transactions, including licensing, strategic alliances, joint ventures, confidentiality, manufacturing, supply, and distribution agreements. Rob's technical background coupled with extensive experience working within the life sciences allows him to bridge the gap between life sciences and computer sciences industries, particularly in matters related to computational biology and bioinformatics matters.

Rob has extensive experience negotiating complex cross-border collaboration agreements, particularly between the United States and South America, Europe, and Asia, as well as establishing multiparty international drug registries. He also assists clients with evaluating IP in due diligence and negotiates to secure optimal IP positions in connection with the acquisition or divestment of assets in the United States and abroad.

Rob has worked with leading companies in the life sciences and environmental sectors, such as Astellas, Athersys, Biomarin, Celgene, Cibus, Granite Construction, Milliken, NorthStar Group, Organon, Procter & Gamble, and Sanofi.

Rob's technical experience includes small molecule, biologics, gene editing and therapy, medical devices, data management, artificial intelligence, software, and electrical engineering.

Prior to joining Jones Day, Rob was an associate in the San Diego offices of two international law firms where he predominantly worked in patent prosecution and assisted in patent litigation and technology-based transactions. At the start of his career, he practiced intellectual property law in the Columbus, Ohio office of a national law firm.

Experience

  • STERIS sells dental segment to an affiliate of Peak Rock CapitalJones Day is advising STERIS Plc in the $787.5 million sale of Dental segment to Peak Rock Capital, a leading middle-market private investment firm.
  • TransDigm completes additional $550 million Senior Secured Notes offering and reprices $6.2 billion of existing tranche H and I term loansJones Day represented TransDigm Group Incorporated (“TransDigm Group”), a leading global designer, producer, and supplier of highly engineered aircraft components, in connection with the Rule 144A and Regulation S offering by TransDigm Inc., its wholly-owned subsidiary, of an additional $550 million aggregate principal amount of 6.375% Senior Secured Notes due 2029 (the “Notes”).
  • J.F. Lehman & Company acquires Mission MicrowaveJones Day advised J.F. Lehman & Company in the acquisition and financing of all of the outstanding membership interests of Mission Microwave Technologies, LLC, a revolutionary designer of radio frequency and microwave electronics supporting ground-based, airborne and space-based applications.
  • MPE Partners acquires Webster IndustriesJones Day advised MPE Partners in the acquisition and financing of Webster Industries, Inc., an industrial equipment supplier focused on engineered class chains, sprockets, and vibrating equipment.
  • Silicon Mobility sold to IntelJones Day advised Silicon Mobility SAS in the acquisition of the company by Intel Corporation.
  • Newell Brands amends $1 billion revolving credit facilityJones Day represented Newell Brands Inc. (“Newell”), a leading consumer products company, in connection with the amendment restructuring its existing revolving credit facility.
  • P&G sells Vidal Sassoon brand in Greater ChinaJones Day is advising The Procter & Gamble Company in the sale of its Vidal Sassoon hair care consumer products business to Henkel AG & Co. KGaA.
  • Signature Aviation acquires MeridianJones Day advised Signature Aviation in the acquisition of Meridian, an award-winning private aviation company with bases in Teterboro, NJ (TEB) and Hayward, CA (HWD).
  • Shiseido Americas acquires Dr. Dennis Gross Skincare for $450 millionJones Day is advising Shiseido Americas Corporation, a subsidiary of Shiseido Co., Ltd., regarding its definitive agreement to acquire DDG Skincare Holdings LLC, the owner of Dr. Dennis Gross Skincare, for $450 million in cash.
  • EagleTree Capital acquires Summit Hill FoodsJones Day advised EagleTree Capital in the acquisition and financing of Summit Hill Foods, Inc., a leading branded food company producing nationally recognized, premium brands, including Better Than Bouillon and The Original Louisiana Hot Sauce.
  • Norwest Equity Partners acquires United Sports BrandsJones Day represented Norwest Equity Partners in the acquisition and financing of United Sports Brands, a global leader in sports performance and protective products, including the Shock Doctor, McDavid, Cutters, Nathan, PEARL iZUMi, and Glukos brands.
  • Sanofi and Janssen collaborate to develop vaccines for extra-intestinal pathogenic E. coliJones Day represented and supported Sanofi's in-house team in its strategic collaboration with Janssen Pharmaceuticals, now "Johnson & Johnson Innovative Medicine," in connection with a Co-Development, Co-Commercialization & License Agreement with Johnson & Johnson's Janssen Pharmaceuticals relating to the development and commercialization of vaccines for extra-intestinal pathogenic E. coli.
  • EagleTree Capital acquires MMGY GlobalJones Day advised EagleTree Capital in the acquisition and financing of MMGY Global, a leading integrated marketing firm specializing in travel, tourism and hospitality, from Peninsula Partners and other shareholders.
  • J.F. Lehman & Company portfolio company acquires White Lake Dock & DredgeJones Day advised J.F. Lehman & Company in the acquisition and financing by portfolio company, ENTACT, LLC, of White Lake Dock & Dredge, Inc.
  • Cibus combines with CalyxtJones Day advised Cibus Global, LLC (“Cibus”), a San Diego based leader in precision gene editing in agriculture, in connection with an all-stock merger with Calyxt, Inc. (NASDAQ: CLXT), under which Cibus and Calyxt created an industry-leading company that combines two pioneers in agriculture-based gene editing and establishes one of the world’s most sophisticated facilities for trait development and plant breeding.
  • Large financial institution provides $275 million senior secured credit facility to dynamic distribution and manufacturing companyJones Day represented a large financial institution, as administrative agent and lead arranger, in connection with senior secured credit facilities in the aggregate amount of $275 million provided to a large multi-divisional distribution and manufacturing company supporting the food service industry, comprised of a $150 million revolving credit facility and a $125 million delayed draw term loan facility.
  • Astellas enters into strategic collaboration and exclusive option license agreement with ImmunoPrecise Antibodies Ltd.Jones Day represented Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas Pharma Inc., "Astellas") in connection with a research collaboration and exclusive option license agreement with ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company.
  • AAR acquires TraxJones Day advised AAR CORP. in the acquisition of Trax USA Corp., a leading independent provider of aircraft MRO and fleet management software, for a purchase price of $120 million in cash, plus up to a $20 million earn-out payment based on specified adjusted revenues in calendar year 2023 and 2024.
  • NioCorp combines with GX Acquisition Corp. IIJones Day advised NioCorp Developments Ltd. (TSX: NB; OTCQX: NIOBF) in its business combination with GX Acquisition Corp. II (Nasdaq: GXII), a publicly-traded special purpose acquisition corporation.
  • EagleTree Capital acquires PRA EventsJones Day represented EagleTree Capital in connection with its acquisition of PRA Events, Inc., a leading business event management firm, from CI Capital Partners.
    • View All

    September 2023 Newsletters

    Vital Signs Digital Health Law Update | Summer 2023

    August 2023 Commentary

    Generative AI End-User License Agreements: What Users Need to Know

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.